Back to results

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Primary Purpose

Acute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative, Aged 60 Years or Older

Status

Withdrawn

Phase

Phase 1

Locations

United States

Study Type

Interventional

Intervention

Erwinia Chrysanthemi asparaginase

About this trial

This is an interventional treatment trial for Acute Lymphoblastic Leukemia (ALL) focused on measuring Erwinia Chrysanthemi Asparaginase, 15-107

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Ages 60 years or older
Previously untreated Philadelphia chromosome negative acute lymphoblastic leukemia
No prior treatment for ALL, except steroids or hydroxyurea (stopped within 24 hour before start of protocol treatment)
Serum creatinine ≤ 2 x upper limit of normal (ULN)
Adequate liver function, including total bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome, and aspartate and alanine aminotransferase (AST and ALT) ≤ 5 x ULN. If organ function abnormalities are considered due to leukemic infiltration, total bilirubin must be ≤ 2 x ULN.
ECOG performance status ≤3
Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for a minimum of 90 days after the last dose of treatment on protocol. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active. Female patients who are not of childbearing potential should meet at least one of the following criteria:
- Have undergone hysterectomy or bilateral oophorectomy; or
- Have medically confirmed ovarian failure; or
- Are medically confirmed to be post-menopausal (cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause

Exclusion Criteria:

Lymphoblastic crisis of CML
Mature B cell (Burkitt's) ALL
Active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of CNS-directed local treatment for active disease within the prior 28 days, symptomatic CNS leukemia (i.e., cranial nerve palsies or other significant neurologic dysfunction) within 28 days. Prophylactic intrathecal medication is not a reason for exclusion.
Pregnant women or women who are breast-feeding
Concurrent active malignancy requiring immediate therapy
Patients with human immunodeficiency virus (HIV)

Sites / Locations

Memorial Sloan Kettering Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Erwinia Chrysanthemi asparaginase

Arm Description

This is a phase I trial designed to assess the safety of IV Erwinia Chrysanthemi asparaginase during initial induction in patients aged 60 years or older with newly diagnosed Ph-negative ALL. A total of 12 patients will be accrued to the study.

Outcomes

Primary Outcome Measures

proportion of patients who have a dose limiting toxicity (DLT)

DLTs are defined as any of the following: grade 4 pancreatitis, grade 4 hemorrhage, grade 4 thromboembolism, grade 4 hyperbilirubinemia and any grade 5 toxicity attributable (definitely, probably or possible) to Erwinia asparaginase.

Secondary Outcome Measures

Full Information

NCT ID

NCT02647190

First Posted

January 5, 2016

Last Updated

June 1, 2017

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

Jazz Pharmaceuticals

1. Study Identification

Unique Protocol Identification Number

NCT02647190

Brief Title

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Official Title

A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Study Type

Interventional

2. Study Status

Record Verification Date

June 2017

Overall Recruitment Status

Withdrawn

Study Start Date

January 2016 (Actual)

Primary Completion Date

June 2017 (Actual)

Study Completion Date

June 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

Jazz Pharmaceuticals

4. Oversight

5. Study Description

Brief Summary

The purpose of this study is to test the safety of Erwinia Chrysanthemi asparaginase when used alone and together with chemotherapy and find out what effects, if any, it has on people.

Detailed Description

The study consists of three treatment phases. Steroid prophase (days -3 to -1): To prevent rapid leukemia progression and reduce tumor load, patients will receive either prednisone 60mg/m2 oral daily or equivalent corticosteroid daily for 3 days. Asparaginase phase (days 1 - 14): Patients will receive Erwinia asparaginase 25,000 IU/m2 IV three times a week on a Monday, Wednesday, Friday (MWF) schedule for 2 weeks. Patients are permitted to begin Erwinia asparaginase on Monday, Wednesday, or Friday, so that their schedules are defined as MWF, WFM, or FMW. For rapid progression of disease (defined by rising WBC >30K with > 50% peripheral blasts), prednisone 60mg/m2 oral daily or equivalent corticosteroid daily may be added. Bone marrow aspirate and/or biopsy will be performed on days 13-15 of the asparaginase treatment for early disease response assessment. Chemotherapy phase (days 15 - 42): Cyclophosphamide 650 mg/m2 IV on day 15 Vincristine 1.4 mg/m2 (max 2mg) IV on days 15, 22, 29, and 36 Prednisone 60mg/m2 (or equivalent corticosteroid) oral daily for 28 days on days 15 - 42 Erwinia asparaginase 25,000 IU/m2 IV three times a week on a MWF schedule for 2 weeks on days 29 - 42 (after a two week interval without Erwinia asparaginase administered on days 1 - 14) Upon cell count recovery, a bone marrow aspirate and/or biopsy will be performed to assess the disease response. Subsequent treatments following the bone marrow evaluation will be left up to the discretion of the treating physicians. If the first 6 patients have no response or progress during the 2 weeks of asparaginase phase of treatment with or without steroid, the next 6 patients will start directly with the chemotherapy phase (days 15-42) of treatment consisting of cyclophosphamide, vincristine, and prednisone with Erwinia asparaginase. CNS prophylaxis: IT methotrexate 12mg (flat dose) between days 15 - 22 IT methotrexate 12mg (flat dose) between days 22- 29 There will be a minimal interval between doses of 7 days

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Acute Lymphoblastic Leukemia (ALL), Newly Diagnosed Philadelphia Chromosome Negative, Aged 60 Years or Older

Keywords

Erwinia Chrysanthemi Asparaginase, 15-107

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

0 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Erwinia Chrysanthemi asparaginase

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Erwinia Chrysanthemi asparaginase

Primary Outcome Measure Information:

Title

proportion of patients who have a dose limiting toxicity (DLT)

Description

Time Frame

with in 6 weeks of starting the study drug

10. Eligibility

Sex

All

Minimum Age & Unit of Time

60 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Ages 60 years or older Previously untreated Philadelphia chromosome negative acute lymphoblastic leukemia No prior treatment for ALL, except steroids or hydroxyurea (stopped within 24 hour before start of protocol treatment) Serum creatinine ≤ 2 x upper limit of normal (ULN) Adequate liver function, including total bilirubin ≤ 1.5 x ULN unless the patient has documented Gilbert syndrome, and aspartate and alanine aminotransferase (AST and ALT) ≤ 5 x ULN. If organ function abnormalities are considered due to leukemic infiltration, total bilirubin must be ≤ 2 x ULN. ECOG performance status ≤3 Male and female patients of childbearing potential must agree to use a highly effective method of contraception throughout the study and for a minimum of 90 days after the last dose of treatment on protocol. A patient is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active. Female patients who are not of childbearing potential should meet at least one of the following criteria: Have undergone hysterectomy or bilateral oophorectomy; or Have medically confirmed ovarian failure; or Are medically confirmed to be post-menopausal (cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause Exclusion Criteria: Lymphoblastic crisis of CML Mature B cell (Burkitt's) ALL Active central nervous system (CNS) leukemia, as defined by unequivocal morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of CNS-directed local treatment for active disease within the prior 28 days, symptomatic CNS leukemia (i.e., cranial nerve palsies or other significant neurologic dysfunction) within 28 days. Prophylactic intrathecal medication is not a reason for exclusion. Pregnant women or women who are breast-feeding Concurrent active malignancy requiring immediate therapy Patients with human immunodeficiency virus (HIV)

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Jae Park, MD

Organizational Affiliation

Memorial Sloan Kettering Cancer Center

Official's Role

Principal Investigator

Facility Information:

Facility Name

Memorial Sloan Kettering Cancer Center

City

New York

State/Province

New York

ZIP/Postal Code

10065

Country

United States

12. IPD Sharing Statement

Links:

URL

https://www.mskcc.org/

Description

Memorial Sloan Kettering Cancer Center

Learn more about this trial

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

We'll reach out to this number within 24 hrs